TOP 10 Clinical trials research in Timonium, Maryland

The Johns Hopkins Women's Center, located at 10753 Falls Road in Timonium, Maryland, is a leading institution in women's health care. Led by Dr. Andrew Satin, our team of experts provides individualized, research-based care for women at every stage of life. Our specialized research programs and innovative treatment options advance the field of gynecology and obstetrics. International patients can easily request appointments through our international patient services. Our top-ranked residency and fellowship programs offer comprehensive training for the next generation of women's health leaders. The center has recently expanded, doubling the number of consult and ultrasound rooms, and adding additional workspace for clinical and nonclinical employees.

Patrick Forde, MD is a renowned institution located at 10753 Falls Road, Timonium, Maryland, United States. Specializing in the treatment of lung cancer, mesothelioma, and other thoracic cancers, Dr. Forde offers state-of-the-art care to his patients. With a background in internal medicine and oncology from Ireland, he currently serves as Co-Director of the Division of Upper Aerodigestive Malignancies at Johns Hopkins Medicine. Dr. Forde's research focuses on immuno-oncology and has led to the development of several ongoing phase 3 trials. His groundbreaking work was recently published in the New England Journal of Medicine, leading to FDA approval for neoadjuvant chemo-immunotherapy in lung cancer treatment. Patients can expect compassionate care from Dr. Forde and his dedicated team of oncology specialists. Despite recent traffic disruptions in the Baltimore region, patients are encouraged to prioritize their health and attend appointments as scheduled. Masks are strongly recommended but not required in Maryland, with a focus on patient safety and well-being. Patients have rated their experiences at Dr. Forde's institution highly, reflecting the exceptional level of care provided.

Deborah Armstrong, M.D. is a healthcare institution located at 10753 Falls Road in Timonium, Maryland, United States. Dr. Armstrong specializes in women's malignancies, with a focus on breast cancer, ovarian cancer, and other gynecologic cancers, as well as the genetics of breast and ovarian cancer. She directs the medical gynecologic oncology clinical service and oversees therapeutic clinical trials in gynecologic cancers. Dr. Armstrong's research focuses on the development of new approaches to prevention, early detection, and treatment of breast cancer and gynecologic malignancies. She is involved in various national and international committees and clinical trials related to cancer research. The institution strongly recommends masks but does not require them. Due to the collapse of the Francis Scott Key Bridge, there may be delays when traveling to appointments. The institution offers services related to breast cancer, cancer genetics, cancer risk, cervical cancer, gynecologic cancers, hereditary breast cancer, medical oncology, and ovarian cancer.

Max Kates, M.D. is a leading institution located in Timonium, Maryland, United States, specializing in urologic oncology. Dr. Max Kates, an Associate Professor of Urology and Oncology, heads the Division of Urologic Oncology at the prestigious Brady Urological Institute. With expertise in bladder and prostate cancer, Dr. Kates offers personalized treatment plans utilizing open, endoscopic, and robotic surgical approaches. He is dedicated to open communication with patients, their families, and referring providers to ensure a speedy recovery. As the clinical director of the bladder cancer multidisciplinary clinic at Johns Hopkins Greenberg Bladder Cancer Institute, Dr. Kates collaborates with a team to deliver cutting-edge precision medicine approaches for bladder cancer patients. His research interests focus on novel treatments for urinary tract cancers, with over 135 journal articles to his credit. Dr. Kates is also the principal investigator on multiple trials, including the groundbreaking EA8212 BRIDGE trial comparing BCG to GemDoce chemotherapy for early stage bladder cancer.